Acute intranigral homocysteine administration produces stereotypic behavioral changes and striatal dopamine depletion in Sprague-Dawley rats

Brain Research

Volumn 1075, Issue 1, 2006, Pages 81-92

  Chandra, Goutam ^a   Gangopadhyay, Prasanta K ^b   Senthil Kumar, Karuppagounder S ^a   Mohanakumar, Kochupurackal P ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

^b BANGUR INSTITUTE OF NEUROLOGY   (India)

Author keywords

Folic acid metabolism; Homocysteine; l DOPA side effect; Parkinson's disease; Stereotypic behavior

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; AMPHETAMINE; APOMORPHINE; DOPAMINE; HOMOCYSTEINE; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; STEREOTYPY;

ANIMALS; BODY WEIGHT; CORPUS STRIATUM; DOPAMINE; FUNCTIONAL LATERALITY; HOMOCYSTEINE; INFUSIONS, PARENTERAL; MALE; RATS; RATS, SPRAGUE-DAWLEY; STEREOTYPED BEHAVIOR; SUBSTANTIA NIGRA;

ANIMALIA; PARKINSONIA;

EID: 33644903828     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2005.12.073     Document Type: Article

References (75)

1. R.L. Albin, A.B. Young, and J.B. Penney The functional anatomy of basal ganglia disorders Trends Neurosci. 12 1989 366 375
2. P. Allain, A. Le Bouil, E. Cordillet, L. Le Quay, H. Bagheri, and J.L. Montastruc Sulfate and cysteine levels in the plasma of patients with Parkinson's disease Neurotoxicology 16 1995 527 529
3. R.H. Allen, S.P. Stabler, and J. Lindenbaum Relevance of vitamins, homocysteine and other metabolites in neuropsychiatric disorders Eur. J. Pediatr. 157 1998 S122 S126
4. A. Andersson, L. Brattstrom, B. Israelsson, A. Isaksson, A. Hamfelt, and B. Hultberg Plasma homocysteine before and after methionine loading with regard to age, gender, and menopausal status Eur. J. Clin. Invest. 22 1992 79 87
5. J. Andrich, C. Saft, A. Arz, B. Schneider, M.W. Agelink, P.H. Kraus, W. Kuhn, and T. Muller Hyperhomocysteinaemia in treated patients with Huntington's disease homocysteine in HD Mov. Disord. 19 2004 226 228
6. (2A) receptor antagonist treatment of Parkinson's disease Neurology 61 2003 293 296
7. B.C. Blount, M.M. Mack, C.M. Wehr, J.T. MacGregor, R.A. Hiatt, G. Wang, S.N. Wickramasinghe, R.B. Everson, and B.N. Ames Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: implications for cancer and neuronal damage Proc. Natl. Acad. Sci. U. S. A. 94 1997 3290 3295
8. L. Brattstrom, A. Lindgren, B. Israelsson, A. Andersson, and B. Hultberg Homocysteine and cysteine: determinants of plasma levels in middle-aged and elderly subjects J. Intern. Med. 236 1994 633 641
9. C.G. Charlton Depletion of nigrostriatal and forebrain tyrosine hydroxylase by S-adenosylmethionine: a model that may explain the occurrence of depression in Parkinson's disease Life Sci. 61 1997 495 502
10. C.G. Charlton, and B. Crowell Jr. Striatal dopamine depletion, tremors, and hypokinesia following the intracranial injection of S-adenosylmethionine: a possible role of hypermethylation in parkinsonism Mol. Chem. Neuropathol. 26 1995 269 284
11. H. Cheng, C. Gomes-Trolin, S.M. Aquilonius, A. Steinberg, C. Lofberg, J. Ekblom, and L. Oreland Levels of l-methionine S-adenosyltransferase activity in erythrocytes and concentrations of S-adenosylmethionine and S- adenosylhomocysteine in whole blood of patients with Parkinson's disease Exp. Neurol. 145 1997 580 585
12. R. Clarke, A.D. Smith, K.A. Jobst, H. Refsum, L. Sutton, and P.M. Ueland Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease Arch. Neurol. 55 1998 1449 1455
13. M. Correa, A. Wisniecki, A. Betz, D.R. Dobson, M.F. O'Neill, M.J. O'Neill, and J.D. Salamone The adenosine A2A antagonist KF17837 reverses the locomotor suppression and tremulous jaw movements induced by haloperidol in rats: possible relevance to parkinsonism Behav. Brain Res. 148 2004 47 54
14. RJ. Dobbs, D.D. Lubel, A. Charlett, S.G. Bowes, C.J. O'Neill, C. Weller, and S.M. Dobbs Hypothesis: age-associated changes in gait represent, in part, a tendency towards parkinsonism Age Ageing 21 1992 221 225
15. H. Dorner, P. Otte, and D. Platt Training influence on age-dependent changes in the gait of rats Gerontology 42 1996 7 13
16. W. Duan, B. Ladenheim, R.G. Cutler, I.I. Kruman, J.L. Cadet, and M.P. Mattson Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease J. Neurochem. 80 2002 101 110
17. J.D. Finkelstein Methionine metabolism in mammals J. Nutr. Biochem. 1 1990 228 237
18. J.D. Finkelstein The metabolism of homocysteine: pathways and regulation Eur. J. Pediatr. 157 Suppl. 2 1998 S40 S44
19. E.S. Ford, S.J. Smith, D.F. Stroup, K.K. Steinberg, P.W. Mueller, and S.B. Thacker Homocyst(e)ine and cardiovascular disease: a systematic review of the evidence with special emphasis on case-control studies and nested case-control studies Int. J. Epidemiol. 31 2002 59 70
20. C.G. Gottfries, W. Lehmann, and B. Regland Early diagnosis of cognitive impairment in the elderly with the focus on Alzheimer's disease J. Neural Transm. 105 1998 773 786
21. A. Grieve, S.P. Butcher, and R. Griffiths Synaptosomal plasma membrane transport of excitatory sulphur amino acid transmitter candidates: kinetic characterisation and analysis of carrier specificity J. Neurosci. Res. 32 1992 60 68
22. A. Hartmann, J.D. Troadec, S. Hunot, K. Kikly, B.A. Faucheux, A. Mouatt-Prigent, M. Ruberg, Y. Agid, and E.C. Hirsch Caspase-8 is an effector in apoptotic death of dopaminergic neurons in Parkinson's disease, but pathway inhibition results in neuronal necrosis J. Neurosci. 21 2001 2247 2255
23. L. Hassing, A. Wahlin, B. Winblad, and L. Backman Further evidence on the effects of vitamin B12 and folate levels on episodic memory functioning: a population-based study of healthy very old adults Biol. Psychiatry 45 1999 1472 1480
24. J.M. Henderson, and S.H. Watson Convulsive and postural effects of lesioning the mid-substantia nigra pars reticulata in naive and 6-hydroxydopamine lesioned rats Brain Res. Bull. 60 2003 179 185
25. P.I. Ho, D. Ashline, S. Dhitavat, D. Ortiz, S.C. Collins, T.B. Shea, and E. Rogers Folate deprivation induces neurodegeneration: roles of oxidative stress and increased homocysteine Neurobiol. Dis. 14 2003 32 42
26. R.F. Huang, S.M. Huang, B.S. Lin, J.S. Wei, and T.Z. Liu Homocysteine thiolactone induces apoptotic DNA damage mediated by increased intracellular hydrogen peroxide and caspase 3 activation in HL-60 cells Life Sci. 68 2001 2799 2811
27. INSA Guidelines For Care and Use of Animals in Scientific Research 2000 Indian National Science Academy Publication New Delhi 1 26
28. D. Jasso-Lopez, and R. Tapia Neurotoxic effect of intranigral injection of 1-methyl-4-phenylpyridinium on GABA-containing neurons and its relation to circling behavior J. Neurochem. 64 1995 794 801
29. P. Jenner A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD Neurology 61 Suppl. 6 2003 S32 S38
30. T. Kanda, M.J. Jackson, L.A. Smith, R.K. Pearce, J. Nakamura, H. Kase, Y. Kuwana, and P. Jenner Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys Ann. Neurol. 43 1998 507 513
31. W.K. Kim, and Y.S. Pae Involvement of N-methyl-d-aspartate receptor and free radical in homocysteine-mediated toxicity on rat cerebellar granule cells in culture Neurosci. Lett. 216 1996 117 120
32. K. Klapdor, B.G. Dulfer, A. Hammann, and F.J. Van der Staay A low-cost method to analyse footprint patterns J. Neurosci. Methods 75 1997 49 54
33. I.I. Kruman, C. Culmsee, S.L. Chan, Y. Kruman, Z. Guo, L. Penix, and M.P. Mattson Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity J. Neurosci. 20 2000 6920 6926
34. I.I. Kruman, T.S. Kumaravel, A. Lohani, W.A. Pedersen, R.G. Cutler, Y. Kruman, N. Haughey, J. Lee, M. Evans, and M.P. Mattson Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer's disease J. Neurosci. 22 2002 1752 1762
35. W. Kuhn, R. Roebroek, H. Blom, D. van Oppenraaij, H. Przuntek, A. Kretschmer, T. Buttner, D. Woitalla, and T. Muller Elevated plasma levels of homocysteine in Parkinson's disease Eur. Neurol. 40 1998 225 227
36. P. Lamberti, S. Zoccolella, G. Iliceto, E. Armenise, A. Fraddosio, M. de Mari, and P. Livrea Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients Mov. Disord. 20 2005 69 72
37. H. Lee, H.J. Kim, J.M. Kim, and N. Chang Effects of dietary folic acid supplementation on cerebrovascular endothelial dysfunction in rats with induced hyperhomocysteinemia Brain Res. 996 2004 139 147
38. E.Y. Lee, H. Chen, K.F.A. Soliman, and C.G. Charlton Effects of homocysteine on the dopaminergic system and behavior in rodents Neurotoxicology 26 2005 361 371
39. S.A. Lipton, W.K. Kim, Y.B. Choi, S. Kumar, D.M. D'Emilia, P.V. Rayudu, D.R. Arnelle, and J.S. Stamler Neurotoxicity associated with dual actions of homocysteine at the N-methyl-d-aspartate receptor Proc. Natl. Acad. Sci. U. S. A. 94 1997 5923 5928
40. H. Matsuda, Y. Akechi, Y. Shimada, K. Terasawa, and H. Watanabe Relationship of the ipsilateral rotation in night period and striatal dopamine content reduction in unilateral nigrostriatal 6-OHDA lesioned rats Brain Res. 686 1995 111 114
41. M.P. Mattson, and T.B. Shea Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders Trends Neurosci. 26 2003 137 146
42. A. McCaddon, G. Davies, P. Hudson, S. Tandy, and H. Cattell Total serum homocysteine in senile dementia of Alzheimer type Int. J. Geriatr. Psychiatry 13 1998 235 239
43. J.W. Miller Homocysteine and Alzheimer's disease Nutr. Rev. 57 1999 126 129
44. J.W. Miller, B. Shukitt-Hale, R. Villalobos-Molina, M.R. Nadeau, J. Selhub, and J.A. Joseph Effect of l-DOPA and the catechol-O-methyltransferase inhibitor Ro 41-0960 on sulfur amino acid metabolites in rats Clin. Neuropharmacol. 20 1997 55 66
45. K.P. Mohanakumar, A. de Bartolomeis, R.M. Wu, K.J. Yeh, L.M. Sternberger, S.Y. Peng, D.L. Murphy, and C.C. Chiueh Ferrous-citrate complex and nigral degeneration: evidence for free-radical formation and lipid peroxidation Ann. N. Y. Acad. Sci. 738 1994 392 399
46. T. Muller, B. Werne, B. Fowler, and W. Kuhn Nigral endothelial dysfunction, homocysteine, and Parkinson's disease Lancet 354 1999 126 127
47. T. Muller, D. Woitalla, B. Hauptmann, B. Fowler, and W. Kuhn Decrease of methionine and S-adenosylmethionine and increase of homocysteine in treated patients with Parkinson's disease Neurosci. Lett. 308 2001 54 56
48. T. Muller, H. Hefter, R. Hueber, W.H. Jost, K.L. Leenders, P. Odin, and J. Schwarz Is levodopa toxic? J. Neurol. 251 Suppl. 6 2004 44 46
49. T. Muller, K. Renger, and W. Kuhn Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration Arch. Neurol. 61 2004 657 660
50. D. Muralikrishnan, and K.P. Mohanakumar Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice FASEB J. 12 1998 905 912
51. K. Nilsson, L. Gustafson, R. Faldt, A. Andersson, and B. Hultberg Plasma homocysteine in relation to serum cobalamin and blood folate in a psychogeriatric population Eur. J. Clin. Invest. 24 1994 600 606
52. O. Nygard, S.E. Vollset, H. Refsum, L. Brattstrom, and P.M. Ueland Total homocysteine and cardiovascular disease J. Intern. Med. 246 1999 425 454
53. P.A. Outinen, S.K. Sood, P.C. Liaw, K.D. Sarge, N. Maeda, J. Hirsh, J. Ribau, T.J. Podor, J.I. Weitz, and R.C. Austin Characterization of the stress-inducing effects of homocysteine Biochem. J. 332 1998 213 221
54. P.N. Palma, M.J. Bonifacio, A.I. Loureiro, L.C. Wright, D.A. Learmonth, and P. Soares-da-Silva Molecular modeling and metabolic studies of the interaction of catechol-O-methyltransferase and a new nitrocatechol inhibitor Drug Metab. Dispos. 31 2003 250 258
55. G. Paxinos, and C. Watson The Rat Brain in Stereotaxic Coordinates 4th ed. 1998 Academic Press San Diego 1 120
56. K. Pietrzik, and A. Bronstrup Vitamins B12, B6 and folate as determinants of homocysteine concentration in the healthy population Eur. J. Pediatr. 157 Suppl. 2 1998 S135 S138
57. T. Schuurman, H. Klein, M. Beneke, and J. Traber Nimodipine and motor deficits in the aged rat Neurosci. Res. Commun. 1 1987 9 15
58. J.M. Scott, and D.G. Weir Folic acid, homocysteine and one-carbon metabolism: a review of the essential biochemistry J. Cardiovasc. Risk 5 1998 223 227
59. J. Selhub, P.F. Jacques, A.G. Bostom, P.W. Wilson, and I.H. Rosenberg Relationship between plasma homocysteine and vitamin status in the Framingham study population. Impact of folic acid fortification Public Health Rev. 28 2000 117 145
60. K.M. Sindhu, K.S. Saravanan, and K.P. Mohanakumar Behavioral differences in a rotenone-induced hemiparkinsonian rat model developed following intranigral or median forebrain bundle infusion Brain Res. 1051 2005 25 34
61. R.W. Smithells, S. Sheppard, and C.J. Schorah Vitamin deficiencies and neural tube defects Arch. Dis. Child. 51 1976 944 950
62. D.A. Snowdon, C.L. Tully, C.D. Smith, K.P. Riley, and W.R. Markesbery Serum folate and the severity of atrophy of the neocortex in Alzheimer disease: findings from the Nun study Am. J. Clin. Nutr. 71 2000 993 998
63. + J. Neural. Transm. 74 1988 75 86
64. L. Tjiattas, D.O. Ortiz, S. Dhivant, K. Mitton, E. Rogers, and T.B. Shea Folate deficiency and homocysteine induce toxicity in cultured dorsal root ganglion neurons via cytosolic calcium accumulation Aging Cell 3 2004 71 76
65. U. Ungerstedt Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigrostriatal dopamine system Acta Physiol. Scand., Suppl. 367 1971 69 93
66. U. Ungerstedt, and G.W. Arbuthnott Quantitative recording of rotational behavior in rats after 6-hydroxydopamine lesions of the nigrostriatal dopamine system Brain Res. 24 1970 485 493
67. P. Valkovic, J. Benetin, P. Blazicek, L. Valkovicova, K. Gmitterova, and P. Kukumberg Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients Parkinsonism Relat. Disord. 11 2005 253 256
68. M. van den Berg, M.S. van der Knaap, G.H. Boers, C.D. Stehouwer, J.A. Rauwerda, and J. Valk Hyperhomocysteinaemia; with reference to its neuroradiological aspects Neuroradiology 37 1995 403 411
69. C.E. Van der Zee, T. Schuurman, R.G. van der Hoop, J. Traber, and W.H. Gispen Beneficial effect of nimodipine on peripheral nerve function in aged rats Neurobiol. Aging 11 1990 451 456
70. H.X. Wang, A. Wahlin, H. Basun, J. Fastbom, B. Winblad, and L. Fratiglioni Vitamin B12 and folate in relation to the development of Alzheimer's disease Neurology 56 2001 1188 1194
71. G.N. Welch, and J. Loscalzo Homocysteine and atherothrombosis N. Engl. J. Med. 338 1998 1042 1050
72. K. Yasui, H. Kowa, K. Nakaso, T. Takeshima, and K. Nakashima Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD Neurology 55 2000 437 440
73. K. Yasui, K. Nakaso, H. Kowa, T. Takeshima, and K. Nakashima Levodopa-induced hyperhomocysteinaemia in Parkinson's disease Acta Neurol. Scand. 108 2003 66 67
74. S. Zoccolella, P. Lamberti, E. Armenise, M. de Mari, S.V. Lamberti, R. Mastronardi, A. Fraddosio, G. Iliceto, and P. Livrea Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications Parkinsonism Relat. Disord. 11 2005 131 133
75. S. Zoccolella, P. Lamberti, G. Iliceto, C. Diroma, E. Armenise, G. Defazio, S.V. Lamberti, A. Fraddosio, M. de Mari, and P. Livrea Plasma homocysteine levels in l-DOPA-treated Parkinson's disease patients with cognitive dysfunctions Clin. Chem. Lab. Med. 43 2005 1107 1110